Navigation Links
ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
Date:1/8/2009

ls represent another important milestone in our corporate development. We look forward to advancing these two important studies and ensuring that ThromboGenics continues to enjoy further success in 2009."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
2. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
3. AFFiRiS Begins Development of a Parkinsons Vaccine
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
7. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
8. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
9. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
10. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
11. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: ... protective equipment for all forms of sports, including extreme ... neck brace, announced today that the UISP Lega Motociclismo ... requires all riders to wear a neck brace during ...
(Date:1/23/2015)... 23, 2015  Mallinckrodt plc (NYSE: MNK ) ... a share repurchase program. The open-ended authorization permits the ... plc ordinary shares. "Funding additional initiatives ... as we continue to pursue a range of focused ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... HILL, N.C., March 30, 2012  The launch landscape for ... and payer influence two of the biggest changes facing ... successful new products has never been greater with the ... development costs. In this challenging new launch ...
... PHILADELPHIA, Pennsylvania, March 30, 2012 Shire plc ... biopharmaceutical company, today announced top-line results of the PREVENT2 trial, ... mesalamine in patients with a history of diverticulitis. [ ... countries worldwide including the United States, did not meet the ...
Cached Medicine Technology:Excellence Services Program Helps Guide Pharmaceutical Industry Through the New Product Launch Landscape 2Shire Announces Top-line Results of the PREVENT2 Trial 2Shire Announces Top-line Results of the PREVENT2 Trial 3Shire Announces Top-line Results of the PREVENT2 Trial 4Shire Announces Top-line Results of the PREVENT2 Trial 5
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ has ... (PPHA). The PPHA's passion for others' well-being and shared ... treated for obstructive sleep apnea (OSA) has propelled them into ... the valley. The most recent plans for an event will ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
(Date:1/22/2015)... 2015 Recently, Weddingshe.com has added many trendy ... announced its highest annual revenues in the past three years. ... glamorous wedding dresses. , According to the sales manager of ... promotions for them in 2015. This point can be reflected ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... from Cardiff University in Britain and Andrew Herxheimer from ... the newer antidepressants trigger violent behavior in people who ... were twice as likely to experience a hostile event ... sources of information in the study including data presented ...
... injury patients with moderate to severe memory loss ... according to a study//. ,Researchers, who ... injury at 19 centers across the United States, ... improved among severely impaired patients who took rivastigmine ...
... a small dispensary on the ground floor of a nursing ... last hope for a steady stream// of HIV carriers waiting ... prolong their survival. ,For the likes of ... a stigma and faced with discrimination and high cost of ...
... to haunt the prestigious All India Institute of Medical ... the elections to its resident doctors association (RDA) that ... and students of AIIMS will elect eight representatives including ... the RDA. Sixteen Candidates are contesting the elections that ...
... A study conducted at Dartmouth Medical School in Hanover, New ... among old people is normal//, yet this could be one ... ,Dr. Andrew Saykin and his associates with the ... people who suffered memory loss without dementia, another 40 patients ...
... Scientists have found that Asian-American women have the top life expectancy ... the worst// , with a gap of almost two decades between ... PLoS Medicine online they have found that the life expectancy of ... high-risk urban areas, it was 68.7 years. Leading among the 50 ...
Cached Medicine News:Health News:Drug Improves Memory Loss for Traumatic Brain Injury Patients 2Health News:AIDS Sufferers Turn to British Doctor to Prolong their Survival 2Health News:AIDS Sufferers Turn to British Doctor to Prolong their Survival 3Health News:AIIMS Goes to Polls Amid Reservation Issues 2Health News:Wide Gaps in Life Expectancy in the US 2
Bravo Tubing/Filter Supplies (Ten tubing sets, ten filters)...
... The lower esophhageal sphincter ... without using a separate manometry ... Locator, LES identification accessory kit ... used to locate the LES. ...
Buffer solution is needed to calibrate pH catheters. The specific chloride ion concentration in the Medtronic buffers is required for proper function of your Medtronic pH measurement system. Buffer s...
The WaveMax is one of the most flexible stainless steel stents due to its unique wave design and has the lowest effective profile, accommodating a 6F sheath up to 7 mm....
Medicine Products: